CNSP News and Press, CNS Pharmaceuticals Inc. From 06/04/24

2024-06-04 09:02:04 ET Cns Pharmaceuticals Inc (CNSP) announced stock split at a ratio of 1-for-50 on 2024-06-05 ... Full story available on KlickAnalytics.com

A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 17.9% to $0.1179 on volume of 290,472,504 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 7.1% to $0.6248 on volume of 223,394,331 shares GameStop Corporation (GME) rose 21.0% to $28...

Patients with brain cancer often undergo surgery to treat the disease because this is the recommended treatment for this particular cancer. This doesn’t mean that surgery is always an option , as treatments for patients are often prescribed by their primary care providers. A trial con...

A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...

2024-06-03 08:19:41 ET More on CNS Pharmaceuticals Financial information for CNS Pharmaceuticals Read the full article on Seeking Alpha For further details see: CNS Pharmaceuticals announces reverse stock split

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a firesi...

Live webcast fireside chat on Tuesday, May 21 st at 1:40 PM ET HOUSTON, TX / ACCESSWIRE / May 20, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers i...

2024-05-16 11:53:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips CNS Pharmaceuticals (NASDAQ: CNSP ) just reported results for the first quarter of 2024. CNS Pharmaceuticals reported earnings per share of -41 cents. The company did ...

Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACC...

Scientists from the University of Florida in America have designed a new vaccine for cancer that prompts the immune system to target glioblastoma. Glioblastoma is an aggressive type of cancer that forms in the spinal cord and/or brain. Roughly 19,000 people in the European Union are afflicted...